Trinity Biotech Receives Early Approval from the World Health Organization to Begin Offshore Manufacturing of TrinScreen HIV & Uni-Gold HIV

Core Insights - Trinity Biotech plc has announced an important update regarding its Comprehensive Transformation Plan, which includes transferring the manufacturing of TrinScreen HIV and Uni-Gold HIV to a lower-cost offshore partner [1][2] - The company received earlier than expected approval from the World Health Organization (WHO) for the later-stage manufacturing process of its rapid HIV tests, marking a significant milestone in its transformation efforts [1][2] Company Overview - Trinity Biotech is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors [4] - The company develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory segments, and has recently entered the wearable biosensor industry [4] - Its products are utilized to detect infectious diseases and quantify various chemistry parameters in blood samples, with a distribution network in over 75 countries [4]